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Abstract: As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is 
substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by  
either vaginal or oral route – is followed by relapses in about 30% of cases, within a month from treatment completion. 
This inability to prevent recurrences reflects our lack of knowledge on the origins of BV. Atopobium vaginae has been  
recently reported to be associated with BV in around 80% of the cases and might be involved in the therapeutic failures. 
This review looks at the potential benefits of nifuratel against A. vaginae compared to the standard treatments with metroni-
dazole and clindamycin. In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 g/mL; 
it is active against G. vaginalis and does not affect lactobacilli. Metronidazole is active against A. vaginae only at   
very high concentrations (8-256 g/mL); it is partially active against G. vaginalis and also has no effect on lactobacilli. 
Clindamycin acts against A. vaginae with an MIC lower than 0.125 g/mL and is active on G. vaginalis but it also affects 
lactobacilli, altering the vaginal environment. These observations suggest that nifuratel is probably the most valid thera-
peutic agent for BV treatment. 
Keywords: Antibiotic resistance, Atopobium vaginae, bacterial vaginosis, nifuratel, review. 
BACTERIAL VAGINOSIS  
Epidemiology and Pathogenesis 
  Bacterial vaginosis (BV) is one of the most frequent   
female lower genital tract infections, not only in pregnancy 
but throughout the reproductive life. Studies from Europe 
and the USA have found prevalence between 4.9%   
and 36.0% [1]. The first signs of BV are radical changes   
in the vaginal ecosystem. H202-producing lactobacilli,   
which are present in 96% of women with normal   
vaginal bacterial flora, are markedly reduced or lost, while 
microorganisms like Gardnerella vaginalis and obligate   
anaerobes prevail [2]. The cause of this change is not   
clear [3] and the microorganisms responsible for the shift   
in the flora have still to be identified [4]. BV may be due  
not only to the excessive bacterial growth, but also to the 
formation of a dense bacterial biofilm adherent to the vaginal 
mucosa. 
Which is the Role of the Biofilm? 
  The biofilm formed by Gardnerella vaginalis in BV was 
first identified by electron microscopy as a dense tissue 
strongly adherent to the vaginal epithelium, and made up of 
bacterial cells packed inside a network of polysaccharide 
fibrils [5, 6]. Later, Swidsinki et al., investigating vaginal 
biopsies by bacterial rDNA fluorescent in situ hybridization, 
suggested that the bacterial biofilm played a primary role in 
the development of BV [7]. 
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 Costerton  et al. and Swidsinki et al. found a dense bacte-
rial biofilm, coating at least half the epithelial surface, in 
90% of biopsies from women with BV, and in only 10% of 
healthy women [7, 8]. The presence of the biofilm enables 
the bacterial cells to reach higher concentrations (up to 10
11 
bacteria/mL) than in vaginal fluid and boosts their resistance 
to both the host immune system and the antimicrobials [9, 
10]. In fact, the drugs hardly reach the bacteria, residing   
inside the film in a quiescent state, leading to an up to 1000-
fold antimicrobial decreased activity [9, 11]. This observa-
tion might provide an explanation of the high rates of BV 
relapses [10, 12].  
Complications of BV 
  BV has aroused interest in the last few years being con-
sidered as a predisposing factor for HIV, Type II Herpes 
symplex virus, Chlamydia trachomatis infections, as well as 
for trichomoniasis and gonorrhea [13, 14]; BV can be also a 
cause for complications like late abortion [15], premature 
rupture of the amniotic membrane [16], chorio-amnionitis 
[17], post-partum endometritis [18, 19, 20], and failure of in 
vitro  fertilization and embryo transfer [13, 14]. Particular 
attention has been recently paid to Atopobium vaginae, a 
newly identified bacterium, belonging to the Coriobacte-
riaceae family, which is believed to be at least a partial 
cause of the above mentioned complications [13]. The genus 
Atopobium, described for the first time in 1992, includes 
bacteria previously classified as lactobacilli. Rodriguez first 
identified A. vaginae in a study on vaginal lactobacilli [21]. 
A. vaginae 16s rRNA gene differs from the other species 
belonging to Atopobium genus by approximately 3-8% [22, 
23]; this enabled Rodriguez to identify it as a new species. The 
isolate can be distinguished from A. minutum, A. parvulum,  
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and A. rimae by biochemical tests and protein electrophoresis 
of the whole cell (Table 1). Gram stain shows A. vaginae as 
a small coccus, rounded or oval, or rods, visible as single 
cells, in pairs or in short chains (Fig. 1). 
 
 
Fig. (1). A) Grey-white colonies of A. vaginae after 48h culture in 
anaerobic conditions. B) Gram staining shows Gram-positive bacte-
ria, with A. vaginae visible as single cells, in pairs or short chains. 
Geissdorfer et al. 2003 [41]. 
  This aerobic facultative, gram-positive bacterium cannot 
be easily isolated by classical microbiological methods [14, 
24]. It is hardly detected in healthy women vaginal fluid but 
is commonly found in the vagina of patients with BV: 50% 
according to Burton [25, 26], 70% according to Ferris [27], 
and more than 95% according to Verhelst et al. [24] and 
Verstraelen et al. [28]. In symptomatic BV it has been de-
tected together with Gardnerella vaginalis in the biofilm 
adherent to the vaginal mucosa [24]. This was confirmed by 
Swidsinski et al. [7] who, by examining the composition and 
structural organization of the biofilm, found that Gardnerella 
vaginalis accounted for 60-95% of the film mass. In   
addition, in 70% of bioptic samples, Atopobium vaginae  
accounted for the 1-40% of the film mass. Lactobacillus 
concentrations were lower than 10
6 CFU/mL, making up 
only 5% of the biofilm (Fig. 2). 
Therapy  
  Concerning the pharmacological therapy, CDC recom-
mends either oral or topical (vaginal gel) metronidazole once 
a day for 5 days as first choice for BV. Efficacy is compara-
ble to topical clindamycin [29]. Cure rates, following intrav-
aginal treatment with metronidazole or clindamycin, account 
for 80-90% at the end of treatment and one month after the 
end of therapy [13, 14, 30]. However, three months after the 
end of therapy the rate of relapses can overcome 30%.   
Persistence of an adherent bacterial biofilm, containing 
mostly G. vaginalis and A. vaginae, seems to be the main 
reason for failure of BV treatment [30]. Suppressive treat-
ment with metronidazole gel and physiological approaches 
(use of probiotics or acidifying) have been investigated with  
variable results [31]. Moreover, long-term treatment with 
metronidazole is not recommended because of the high   
incidence of gastrointestinal adverse reactions, the risk of 
peripheral neuropathy, and Candida super infection [32]. 
Table 1.  Biochemical Tests to Distinguish A. vaginae from the other Atopobium Species 
Enzyme   A. vaginae  A. minutum  A. parvulum  A. rimae 
Acid phosphatase  +  -  +  + 
Alanine arylamidase   -  -  +  - 
Arginine dihydrolase   +  +  -  - 
Arginine  arylamidase  + + + - 
Histidine arylamidase  +  -  -  - 
-Galactosidase  - - +  - 
Leucine  arylamidase  + + -  - 
Proline  arylamidase  + + -  - 
Pyroglutamic acid arylamidase   -  v  +  + 
Glycine arylamidase  +  -  +  - 
Serine arylamidase  +  -  -  - 
Thyroxine  arylamidase  - - +  - 
+, the enzyme is expressed constitutively; -, the enzyme is absent and cannot be induced; v, expression of the enzyme is variable 
Modified, from Rodriguez et al. 1999 [21]. 
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Antibiotic Sensitivity 
  Failures with metronidazole in patients with recurrent or 
persistent BV [33, 34] might conceivably reflect the newly 
found mechanism of formation of a biofilm containing   
G. vaginalis together with A. vaginae [7, 9, 13, 28] (Fig. 3). 
The fact that A. vaginae is resistant to metronidazole, and 
that the bacterium creates a biofilm in which it is associated 
with G. vaginalis, complicates the response to the antibiotic 
[9, 13, 28]. Though clindamycin is more active than metron-
idazole against both G. vaginalis and A. vaginae, its negative 
effects on lactobacilli leave the way open to microbial disor-
ders that can cause frequent super infections and recurrences. 
Moreover, an increasing resistance to antibiotics that act like 
clindamycin, by blocking protein synthesis has been reported. 
A randomized  prospective trial compared 119 women   
assigned to two therapeutic regimens for BV: either metroni-
dazole vaginal gel for five days, or clindamycin vaginal tab-
lets for three days. The clinical efficacy was comparable in 
the two arms: after 7-12 days about 80% of the patients were 
cured, but this percentage fell down to about 50% after 35-
45 days. Following clindamycin treatment – but not metron-
idazole - there was a steep rise in the percentage of women 
with at least one clindamycin resistant strain isolated. 
Moreover, 70-90 days after the end of treatment, about 80% 
of the women who received clindamycin presented in their 
vaginal swabs anaerobic bacteria resistant to that drug [35]. 
 Togni  et al. [36] compared the in vitro susceptibility of 
A. vaginae to nifuratel, metronidazole and clindamycin. Sus-
ceptibility to metronidazole was variable, with MIC ranging 
from 8 to 256 g/mL. Nifuratel and clindamycin inhibited 
the growth of all the tested strains, with MIC from 0.125 to 1 
g/mL and below 0.125 g/mL, respectively (Table 2). The 
findings related to metronidazole and clindamycin are in line 
with previously published studies [37].  
 
Table  2.  MIC Ranges (g/mL) and MIC50 ( g/mL) of   
Metronidazole, Clindamycin and Nifuratel against 
Atopobium vaginae 
Antimicrobial Agent  MIC Range (g/ml) MIC50 (g/ml) 
Metronidazole  8 - 256  32 
Clindamycin  < 0.125  < 0.125 
Nifuratel  0.125 - 1  0.5 
Togni et al. 2011 [30]. 
 
  In the same study, the activity of these antibiotics was 
assayed on lactobacilli and G. vaginalis. Either nifuratel and 
metronidazole did not affect the normal lactobacterial flora, 
while clindamycin inhibited all tested strains of lactobacilli. 
Nifuratel and metronidazole were both highly active against 
G. vaginalis (Fig. 4). The susceptibility of Atopobium  
vaginae to metronidazole and clindamycin, and the action   
on lactobacilli and G. vaginalis were in line with previous 
reports [37-39]. To summarise, nifuratel was active against 
A. vaginae and G. vaginalis strains without affecting lacto-
bacilli;  metronidazole was active against A. vaginae, but 
only at very high concentrations, partially active against G. 
vaginalis, and did not affect lactobacilli; clindamycin was 
extremely effective against A. vaginae and G. vaginalis, but it 
also affected the lactobacilli, altering the vaginal ecosystem. 
CONCLUSIONS 
  The discovery of the presence of Atopobium vaginae in 
the vaginal ecosystem improves the basic understanding of 
 
Fig. (2). These microscopy images (A,B,C) show an unbroken 
Gardnerella vaginalis biofilm completely coating the vaginal epi-
thelium. The lower panels show the same microscopic field (Ca) in 
dark-red fluorescence and (Cb) in orange fluorescence. Lactoba-
cilli, interwoven with G. vaginalis in the film, only account for 5% 
of the bacterial population. Swidsinki et al. 2005 [7]. 
 
 
Fig. (3). Microscopic images of the biofilm during and after treat-
ment with metronidazole. A) Bacterial biofilm (x 400) in a patient 
at the third day of metronidazole therapy. The film is thin. B)  
Bacterial biofilm (x 400) in the same patient on day 35. The film 
has reformed almost completely. Swidsinki et al. 2008 [9]. 
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the pathogenesis of BV [28]. This bacterium is presumably 
the main reason for failures or recurrences after BV treat-
ment with metronidazole, since it is found in 80-90% of 
cases of relapse [40]. Prospective studies are now needed to 
show whether metronidazole–resistant microorganisms, such 
as Atopobium vaginae, are involved in recurrences. Informa-
tion to date suggests that nifuratel is probably the most valid 
therapeutic agent for BV, as it is highly active against 
Gardnerella vaginalis and  Atopobium vaginae, without  
affecting lactobacilli which are fundamental for the system 
health and balance [30]. 
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